FIFARMA and ALAFARPE, presented the results of the study “Analysis of access to innovative medicines in Peru compared to OECD countries” on April 9th, within the framework of the Foro Innovación en Salud: Nuevas Tecnologías para el Bienestar de los Peruanos /Forum Innovation in Health: New Technologies for the Wellbeing of Peruvians. The event was held at the prestigious Universidad del Pacífico, in Lima, Peru and was attended by prominent exhibitors from the biopharmaceutical industry, as well as, from government and academia.
The study was requested by FIFARMA and ALAFARPE to IQVIA, a world leader in services, information and technology for the health sector. The analysis compared the registration and reimbursement timeframes for 247 innovative molecules in Peru as compared to 23 OECD member countries.
Among the main findings of the report, presenters highlighted that:
– In Peru it takes five years on average for a medicine, to obtain its sanitary registration and be included in a medication request, that is, for patients to access them.
– The term for the sanitary registration of innovative medicines has doubled in just six years: in 2012, the average was 6 months, while in 2018 it reached a waiting period of 15 months.
– Only 18 of the 110 molecules registered in Peru are covered by Minsa and EsSalud, which makes it difficult for patients to access new technologies.
In conclusion, Ángela Flores, Executive Director of ALAFARPE, stated that this situation represents a great challenge for Peru, since the main goal is to guarantee the population’s access to innovative medicines. “This is a critical issue, especially for the most vulnerable patients, such as those suffering from cancer, chronic and orphan diseases, since this type of treatment could represent their only treatment option,” she said.
FIFARMA, meanwhile, was represented at this event by Juan Carlos Trujillo, Director of International Policies and Operations of the Federation, who declared: “It is necessary, for the wellbeing of the population, that the public and private sectors develop more spaces for dialogue in order to be able to generate proposals which contribute to overcome the those possible barriers to access to innovation in health, that may exist “.
Author: María Alejandra De Guzmán – FIFARMA Communications Manager.